LEMAITRE VASCULAR INC (LMAT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:LMAT • US5255582018

87.42 USD
+0.43 (+0.49%)
At close: Feb 6, 2026
87.42 USD
0 (0%)
After Hours: 2/6/2026, 4:30:00 PM
Fundamental Rating

7

Overall LMAT gets a fundamental rating of 7 out of 10. We evaluated LMAT against 186 industry peers in the Health Care Equipment & Supplies industry. LMAT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. LMAT has a correct valuation and a medium growth rate. With these ratings, LMAT could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • LMAT had positive earnings in the past year.
  • LMAT had a positive operating cash flow in the past year.
  • Each year in the past 5 years LMAT has been profitable.
  • LMAT had a positive operating cash flow in each of the past 5 years.
LMAT Yearly Net Income VS EBIT VS OCF VS FCFLMAT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M

1.2 Ratios

  • LMAT has a better Return On Assets (8.92%) than 91.40% of its industry peers.
  • LMAT's Return On Equity of 14.08% is amongst the best of the industry. LMAT outperforms 89.78% of its industry peers.
  • With an excellent Return On Invested Capital value of 8.43%, LMAT belongs to the best of the industry, outperforming 87.10% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for LMAT is in line with the industry average of 8.80%.
  • The last Return On Invested Capital (8.43%) for LMAT is above the 3 year average (8.26%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 8.92%
ROE 14.08%
ROIC 8.43%
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
LMAT Yearly ROA, ROE, ROICLMAT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15

1.3 Margins

  • The Profit Margin of LMAT (22.14%) is better than 94.62% of its industry peers.
  • LMAT's Profit Margin has improved in the last couple of years.
  • With an excellent Operating Margin value of 25.71%, LMAT belongs to the best of the industry, outperforming 95.16% of the companies in the same industry.
  • LMAT's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 70.97%, LMAT belongs to the best of the industry, outperforming 80.11% of the companies in the same industry.
  • LMAT's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 25.71%
PM (TTM) 22.14%
GM 70.97%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
LMAT Yearly Profit, Operating, Gross MarginsLMAT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), LMAT is destroying value.
  • Compared to 1 year ago, LMAT has more shares outstanding
  • LMAT has more shares outstanding than it did 5 years ago.
  • Compared to 1 year ago, LMAT has a worse debt to assets ratio.
LMAT Yearly Shares OutstandingLMAT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
LMAT Yearly Total Debt VS Total AssetsLMAT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 7.40 indicates that LMAT is not in any danger for bankruptcy at the moment.
  • LMAT's Altman-Z score of 7.40 is amongst the best of the industry. LMAT outperforms 86.02% of its industry peers.
  • LMAT has a debt to FCF ratio of 2.54. This is a good value and a sign of high solvency as LMAT would need 2.54 years to pay back of all of its debts.
  • LMAT has a Debt to FCF ratio of 2.54. This is amongst the best in the industry. LMAT outperforms 84.41% of its industry peers.
  • LMAT has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
  • LMAT's Debt to Equity ratio of 0.44 is in line compared to the rest of the industry. LMAT outperforms 46.24% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 2.54
Altman-Z 7.4
ROIC/WACC0.84
WACC10.02%
LMAT Yearly LT Debt VS Equity VS FCFLMAT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.3 Liquidity

  • A Current Ratio of 13.58 indicates that LMAT has no problem at all paying its short term obligations.
  • LMAT has a better Current ratio (13.58) than 97.85% of its industry peers.
  • A Quick Ratio of 11.45 indicates that LMAT has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 11.45, LMAT belongs to the best of the industry, outperforming 95.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.58
Quick Ratio 11.45
LMAT Yearly Current Assets VS Current LiabilitesLMAT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • LMAT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.67%, which is quite good.
  • Measured over the past years, LMAT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 17.13% on average per year.
  • Looking at the last year, LMAT shows a quite strong growth in Revenue. The Revenue has grown by 13.07% in the last year.
  • Measured over the past years, LMAT shows a quite strong growth in Revenue. The Revenue has been growing by 13.41% on average per year.
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%

3.2 Future

  • LMAT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.10% yearly.
  • Based on estimates for the next years, LMAT will show a quite strong growth in Revenue. The Revenue will grow by 9.65% on average per year.
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%

3.3 Evolution

  • Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LMAT Yearly Revenue VS EstimatesLMAT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
LMAT Yearly EPS VS EstimatesLMAT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • LMAT is valuated quite expensively with a Price/Earnings ratio of 39.92.
  • Compared to the rest of the industry, the Price/Earnings ratio of LMAT indicates a somewhat cheap valuation: LMAT is cheaper than 70.43% of the companies listed in the same industry.
  • LMAT is valuated rather expensively when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
  • With a Price/Forward Earnings ratio of 33.13, LMAT can be considered very expensive at the moment.
  • LMAT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. LMAT is cheaper than 70.97% of the companies in the same industry.
  • The average S&P500 Price/Forward Earnings ratio is at 27.20. LMAT is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 39.92
Fwd PE 33.13
LMAT Price Earnings VS Forward Price EarningsLMAT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, LMAT is valued a bit cheaper than the industry average as 75.27% of the companies are valued more expensively.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of LMAT indicates a rather cheap valuation: LMAT is cheaper than 80.11% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 29.95
EV/EBITDA 20.51
LMAT Per share dataLMAT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • LMAT has an outstanding profitability rating, which may justify a higher PE ratio.
  • A more expensive valuation may be justified as LMAT's earnings are expected to grow with 14.06% in the coming years.
PEG (NY)1.45
PEG (5Y)2.33
EPS Next 2Y16.63%
EPS Next 3Y14.06%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a yearly dividend of 0.95%, LMAT is not a good candidate for dividend investing.
  • LMAT's Dividend Yield is rather good when compared to the industry average which is at 0.21. LMAT pays more dividend than 93.01% of the companies in the same industry.
  • With a Dividend Yield of 0.95, LMAT pays less dividend than the S&P500 average, which is at 1.82.
Industry RankSector Rank
Dividend Yield 0.95%

5.2 History

  • On average, the dividend of LMAT grows each year by 13.60%, which is quite nice.
  • LMAT has paid a dividend for at least 10 years, which is a reliable track record.
  • LMAT has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)13.6%
Div Incr Years13
Div Non Decr Years13
LMAT Yearly Dividends per shareLMAT Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0.2 0.4 0.6

5.3 Sustainability

  • LMAT pays out 32.20% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of LMAT is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP32.2%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
LMAT Yearly Income VS Free CF VS DividendLMAT Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
LMAT Dividend Payout.LMAT Dividend Payout, showing the Payout Ratio.LMAT Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

LEMAITRE VASCULAR INC

NASDAQ:LMAT (2/6/2026, 4:30:00 PM)

After market: 87.42 0 (0%)

87.42

+0.43 (+0.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06
Earnings (Next)02-19
Inst Owners95.2%
Inst Owner Change5.58%
Ins Owners7.98%
Ins Owner Change-4.55%
Market Cap1.98B
Revenue(TTM)240.87M
Net Income(TTM)53.34M
Analysts78.82
Price Target105.74 (20.96%)
Short Float %5.88%
Short Ratio7.21
Dividend
Industry RankSector Rank
Dividend Yield 0.95%
Yearly Dividend0.64
Dividend Growth(5Y)13.6%
DP32.2%
Div Incr Years13
Div Non Decr Years13
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.59%
Min EPS beat(2)3.81%
Max EPS beat(2)7.38%
EPS beat(4)2
Avg EPS beat(4)0.79%
Min EPS beat(4)-5.52%
Max EPS beat(4)7.38%
EPS beat(8)6
Avg EPS beat(8)4.68%
EPS beat(12)9
Avg EPS beat(12)4.66%
EPS beat(16)9
Avg EPS beat(16)-0.71%
Revenue beat(2)1
Avg Revenue beat(2)-1.47%
Min Revenue beat(2)-3.74%
Max Revenue beat(2)0.79%
Revenue beat(4)2
Avg Revenue beat(4)-0.88%
Min Revenue beat(4)-3.74%
Max Revenue beat(4)1.83%
Revenue beat(8)4
Avg Revenue beat(8)-0.49%
Revenue beat(12)6
Avg Revenue beat(12)-0.01%
Revenue beat(16)7
Avg Revenue beat(16)-0.44%
PT rev (1m)0%
PT rev (3m)-0.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.33%
EPS NY rev (1m)0%
EPS NY rev (3m)6.3%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.94%
Valuation
Industry RankSector Rank
PE 39.92
Fwd PE 33.13
P/S 8.24
P/FCF 29.95
P/OCF 27.07
P/B 5.23
P/tB 7.05
EV/EBITDA 20.51
EPS(TTM)2.19
EY2.51%
EPS(NY)2.64
Fwd EY3.02%
FCF(TTM)2.92
FCFY3.34%
OCF(TTM)3.23
OCFY3.69%
SpS10.62
BVpS16.7
TBVpS12.4
PEG (NY)1.45
PEG (5Y)2.33
Graham Number28.69
Profitability
Industry RankSector Rank
ROA 8.92%
ROE 14.08%
ROCE 10.97%
ROIC 8.43%
ROICexc 21.47%
ROICexgc 38.36%
OM 25.71%
PM (TTM) 22.14%
GM 70.97%
FCFM 27.5%
ROA(3y)7.77%
ROA(5y)8.17%
ROE(3y)10.28%
ROE(5y)10.74%
ROIC(3y)8.26%
ROIC(5y)8.93%
ROICexc(3y)14.32%
ROICexc(5y)13.54%
ROICexgc(3y)28.83%
ROICexgc(5y)29.82%
ROCE(3y)10.75%
ROCE(5y)11.62%
ROICexgc growth 3Y-0.4%
ROICexgc growth 5Y7.52%
ROICexc growth 3Y9.22%
ROICexc growth 5Y8.43%
OM growth 3Y0.27%
OM growth 5Y5.61%
PM growth 3Y4.76%
PM growth 5Y5.57%
GM growth 3Y1.48%
GM growth 5Y0.13%
F-Score5
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 2.54
Debt/EBITDA 2.33
Cap/Depr 68.51%
Cap/Sales 2.93%
Interest Coverage 250
Cash Conversion 101.46%
Profit Quality 124.17%
Current Ratio 13.58
Quick Ratio 11.45
Altman-Z 7.4
F-Score5
WACC10.02%
ROIC/WACC0.84
Cap/Depr(3y)60.87%
Cap/Depr(5y)52.43%
Cap/Sales(3y)2.97%
Cap/Sales(5y)2.88%
Profit Quality(3y)96.62%
Profit Quality(5y)110.46%
High Growth Momentum
Growth
EPS 1Y (TTM)19.67%
EPS 3Y15.47%
EPS 5Y17.13%
EPS Q2Q%26.53%
EPS Next Y27.49%
EPS Next 2Y16.63%
EPS Next 3Y14.06%
EPS Next 5Y11.1%
Revenue 1Y (TTM)13.07%
Revenue growth 3Y12.5%
Revenue growth 5Y13.41%
Sales Q2Q%11.36%
Revenue Next Year12.78%
Revenue Next 2Y10.91%
Revenue Next 3Y10.19%
Revenue Next 5Y9.65%
EBIT growth 1Y24.85%
EBIT growth 3Y12.81%
EBIT growth 5Y19.77%
EBIT Next Year47.11%
EBIT Next 3Y23.04%
EBIT Next 5YN/A
FCF growth 1Y189.96%
FCF growth 3Y7.14%
FCF growth 5Y28.96%
OCF growth 1Y143.52%
OCF growth 3Y7.93%
OCF growth 5Y25.49%

LEMAITRE VASCULAR INC / LMAT FAQ

What is the ChartMill fundamental rating of LEMAITRE VASCULAR INC (LMAT) stock?

ChartMill assigns a fundamental rating of 7 / 10 to LMAT.


What is the valuation status of LEMAITRE VASCULAR INC (LMAT) stock?

ChartMill assigns a valuation rating of 5 / 10 to LEMAITRE VASCULAR INC (LMAT). This can be considered as Fairly Valued.


How profitable is LEMAITRE VASCULAR INC (LMAT) stock?

LEMAITRE VASCULAR INC (LMAT) has a profitability rating of 9 / 10.


What is the valuation of LEMAITRE VASCULAR INC based on its PE and PB ratios?

The Price/Earnings (PE) ratio for LEMAITRE VASCULAR INC (LMAT) is 39.92 and the Price/Book (PB) ratio is 5.23.


How financially healthy is LEMAITRE VASCULAR INC?

The financial health rating of LEMAITRE VASCULAR INC (LMAT) is 7 / 10.